HIV genotyping provides susceptibility information for integrase inhibitors (INI). Intended for patients with viral load >500 copies/mL.
Reverse Transcription Polymerase Chain Reaction/Sequencing
Lavender (EDTA), pink (K2EDTA), or plasma preparation tube.
Separate plasma from cells within 6 hours. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)
Serum. Heparinized specimens.
Please submit most recent viral load and test date, if available.
On cells: Ambient: 6 hours; After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 4 months
The entire integrase-encoding region is sequenced. Mutations associated with resistance to integrase inhibitors are reported. Mutations in viral sub-populations below 20 percent of total may not be detected.
Laboratory Developed Test (LDT)
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 HIV-1 RNA copies per mL of plasma.
|Component Test Code*||Component Chart Name||LOINC|
|2004458||HIV-1 Integrase Inhib. Resistance, Seq||72560-6|
- HIV Drug Resistance
- HIV Integrase Genotype
- HIV Integrase Inhibitor Resistance
- HIV Treatment Susceptibility Testing
- HIV1 Integrase Resistance
- HIV1 Integrase Sequencing
- HIV1 Sequencing
- Raltegravir (Isentress(TM)) Resistance